MannKind (NNFN) Stock Price & Analysis
NNFN Stock Chart & Stats
- Day’s Range
- EUR 3.08 - EUR 3.08
- 52-Week Range
- EUR 1.93 - EUR 5.24
- Previous Close
- EUR 3.04
- Volume
- N/A
- Average Volume (3M)
- 62
- Market Cap
- EUR 1.01B
- Enterprise Value
- EUR 1.64B
- Total Cash (Recent Filing)
- EUR 111.13M
- Total Debt (Recent Filing)
- EUR 330.85M
- Price to Earnings (P/E)
- ―
- Beta
- 0.73
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- -0.06
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross Margin
The sustained revenue ramp and high gross margin indicate that MannKind is gaining commercial traction while retaining attractive product economics. If maintained, this combination can support reinvestment in launches and development, strengthen operating leverage, and improve the durability of future earnings.
Diversifying Marketed Product Base
Growth is increasingly coming from marketed products rather than relying primarily on royalties or collaboration revenue. A broader commercial base across Afrezza and FUROSCIX can improve control over growth, expand recurring demand, and create more opportunities to leverage MannKind’s inhalation and delivery capabilities.
ReadyFlow Margin Expansion
ReadyFlow creates a potentially meaningful structural improvement in FUROSCIX economics, not merely a temporary sales benefit. With management expecting most FUROSCIX volume to use ReadyFlow in 2027, the transition could lift contribution margins and improve the profitability of continued product growth.
Bears Say
Stressed Capital Structure
Negative equity and substantial debt reduce MannKind’s financial cushion and make the business more dependent on successful execution or external capital. This structure can constrain investment flexibility, increase pressure during operating setbacks, and amplify the consequences if commercial results weaken.
Inconsistent Profitability And Cash Generation
The return to operating and free-cash-flow burn shows that revenue growth has not yet translated into consistently self-funded operations. Continued losses can consume liquidity, limit the ability to finance launches and development internally, and make future profitability more sensitive to expense control and execution.
Market Access And Affordability Friction
High cash-pay exposure and patient affordability barriers can slow prescription conversion, refill persistence, and broader adoption even when clinical demand exists. Resolving payer coverage and assistance constraints is therefore important to turning launch activity into durable, reimbursed revenue growth.
MannKind News
MannKind’s MNKD-201 Trial: A New Inhaled Bet on Idiopathic Pulmonary Fibrosis
MannKind Corporation ($MNKD) announced an update on their ongoing clinical study. MannKind Corporation’s latest study, “A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Clinical Trial of the Efficacy and Safety of MNKD-201
NNFN FAQ
What was MannKind’s price range in the past 12 months?
What is MannKind’s market cap?
When is MannKind’s upcoming earnings report date?
How were MannKind’s earnings last quarter?
Is MannKind overvalued?
Does MannKind pay dividends?
What is MannKind’s EPS estimate?
How many shares outstanding does MannKind have?
What happened to MannKind’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MannKind?
What is the TipRanks Smart Score and how is it calculated?
MannKind Stock Smart Score
Company Description
MannKind
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael E. Castagna
- Employees
- 592
- Website
- www.mannkindcorp.com
- Address
- 1 Casper Street, Danbury, CA, 06810, US
MannKind (NNFN) Earnings & Revenues
NNFN Company Deck
NNFN Earnings Call
Earnings Call SentimentPositive
The call was strongly optimistic, with management reporting delivery of all three 2026 catalysts, 43% year-over-year quarterly revenue growth, strong early Afrezza pediatric adoption, FUROSCIX growth, ReadyFlow approval, and positive nintedanib safety results. The main negatives were the quarterly net loss, significantly higher operating expenses, Afrezza adult softness and payer friction, FUROSCIX affordability and second-half execution requirements, the ReadyFlow supply-chain delay, and continued regulatory uncertainty for nintedanib. The number and significance of the stated achievements outweighed the challenges.
View all DE:NNFN earnings summariesNNFN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 8 |
| Technical Analysis | 3 | 3 | 3 |
| Moving Averages | 7 | 0 | 5 |
